Genovate Biotechnology Co., Ltd. (TPEX:4130)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
33.65
+0.15 (0.45%)
Jan 22, 2026, 10:30 AM CST
44.82%
Market Cap3.83B
Revenue (ttm)491.23M
Net Income (ttm)10.93M
Shares Out113.75M
EPS (ttm)0.10
PE Ratio350.33
Forward PEn/a
Dividend0.10 (0.29%)
Ex-Dividend DateAug 20, 2025
Volume867,829
Average Volume3,349,293
Open34.30
Previous Close33.65
Day's Range33.40 - 34.50
52-Week Range17.65 - 40.15
Beta0.25
RSI62.43
Earnings DateMar 26, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1982
Employees 195
Stock Exchange Taipei Exchange
Ticker Symbol 4130
Full Company Profile

Financial Performance

In 2024, Genovate Biotechnology's revenue was 510.86 million, a decrease of -3.34% compared to the previous year's 528.51 million. Earnings were 25.70 million, a decrease of -12.40%.

Financial Statements